Summarized & reviewed by The Peptide Dispatch Editorial Team · Last reviewed August 31, 2026
The number everyone argues about may not be a number Men on hormone protocols spend a lot of energy on one line of the panel. Estradiol. It gets screenshotted, compared, tracked week over week, and treated as the single value that explains how things are going. Almost nobody asks the prior question. Was it measured correctly? For most markers that question is boring, because the measurement is…
This dispatch covers Your Estradiol Was Measured by a Test That Misses 87% of Low Readings in Men in the research research category, authored by The Peptide Dispatch Editorial Team. Estimated reading time: 10 minutes. The Peptide Dispatch curates peer-reviewed peptide research for self-directed learners. All summaries are presented for Research Use Only and do not constitute medical advice.
Men on hormone protocols spend a lot of energy on one line of the panel. Estradiol. It gets screenshotted, compared, tracked week over week, and treated as the single value that explains how things are going.
Almost nobody asks the prior question. Was it measured correctly?
For most markers that question is boring, because the measurement is settled and the argument is about where to draw the line. Estradiol in men is different. Here the argument about where to draw the line is happening on top of a measurement that, in the range where men actually live, does not work.
Standard hormone panels run on platform immunoassays. An antibody binds the target molecule and the instrument converts that binding into a concentration. Fast, cheap, high throughput, and for most analytes perfectly adequate.
These assays were built and validated where the clinical demand was: measuring estradiol in women, at concentrations running from roughly 30 pg/mL to several hundred, and far higher in pregnancy.
Adult men run an order of magnitude below that. In a mass spectrometry reference series drawn from more than 900 healthy subjects, median total estrogen concentration in men (estrone plus estradiol combined) was 39 pg/mL, with estradiol accounting for roughly half.
So the antibody is being asked to work near the bottom of its dynamic range. Down there, anything in the sample that structurally resembles estradiol contributes signal, and there is no mechanism in the method to tell the difference.
The European Male Ageing Study took 3,174 men aged 40 to 79 and ran the same serum two ways: a widely used automated platform immunoassay, and in-house gas chromatography mass spectrometry.
Testosterone held up. Correlation between the two methods was R = 0.93 across the range, and R = 0.72 in the hypogonadal range specifically. The immunoassay detected low testosterone with 75% sensitivity and 96.3% specificity. Not perfect, but usable.
Estradiol did not hold up. Below 40.8 pmol/L (about 11 pg/mL), correlation between the two methods was R = 0.32.
Then the number that should end the conversation. Using mass spectrometry as the reference, the immunoassay identified low estradiol with 13.3% sensitivity. Specificity was 99.3%.
In plain terms: if a man genuinely has low estradiol, this assay finds it roughly one time in seven.
At the high end the same assay behaved reasonably, at 88.4% sensitivity and 88.6% specificity for estradiol above 120 pmol/L (about 33 pg/mL). The authors stated the conclusion directly: the immunoassay may only be suitable for detecting high estradiol in men.
An assay that works in one direction is not a monitoring tool. It is a screening test for one narrow question, being used as though it were a dial.
Random error at least averages out over repeat draws. This does not.
A study pooling three cohorts of middle-aged and older men, more than 6,000 subjects across Sweden, the United States, and Europe, compared immunoassay and mass spectrometry estradiol against clinical outcomes. Correlation between methods was moderate, at 0.53 to 0.76 depending on cohort.
The finding that matters is what the two numbers associated with. C-reactive protein, the standard inflammation marker, associated significantly with immunoassay estradiol. It did not associate with mass spectrometry estradiol.
And immunoassay estradiol associated inversely with ankle brachial index, a vascular measure. Mass spectrometry estradiol did not. That association also disappeared once the analysis adjusted for CRP.
Two consequences follow, and the second is the serious one.
First, two men with identical true estradiol but different inflammatory burden can be handed different numbers. The assay is reading something that is not estradiol and is reporting it as estradiol.
Second, a published clinical association between estradiol and vascular disease existed only in the immunoassay data. The better measurement erased it. The authors called for a reevaluation of prior association studies between immunoassay estradiol and inflammation-related outcomes.
Same tube of blood, same instrument, same run, opposite outcome. The reason is concentration.
A man at 600 ng/dL total testosterone is carrying roughly 21 nmol/L of it. A man at 20 pg/mL estradiol is carrying roughly 0.07 nmol/L. Testosterone circulates at something like 300 times the molar concentration of estradiol.
Cross-reacting interference that is trivially small against testosterone is material against estradiol. The absolute error is similar. The relative error is not.
This asymmetry shows up every time anyone looks. A Mayo comparison in 313 men found testosterone by immunoassay correlated with mass spectrometry at R = 0.90, while total estradiol managed R = 0.63. An NCI reproducibility study across twelve steroid metabolites found intraclass correlations above 80% for everything measured by radioimmunoassay except estradiol, which came in at 71.7%, and noted that the immunoassay read markedly higher than mass spectrometry.
The panel is not uniformly reliable. It is reliable for testosterone and unreliable for estradiol, and it prints them one line apart in identical formatting with equally confident reference ranges.
The clinical literature on estradiol in men is genuinely contradictory, and the measurement problem is part of why.
Four studies, four directions:
A Swedish cohort of 3,014 older men, measured by gas chromatography mass spectrometry, found that low estradiol predicted all-cause mortality, hazard ratio 1.54. Men low in both testosterone and estradiol had nearly double the mortality risk of men in the upper three quartiles of both.
A French cohort of 782 men found the opposite. Higher estradiol predicted mortality after year three, hazard ratio 2.83 comparing the top quartile to the bottom.
A study of 501 men with systolic heart failure found a U-shape. Compared with the middle quintile, the lowest estradiol quintile carried a hazard ratio of 4.17 and the highest carried 2.33. Three-year survival was 44.6% in the lowest quintile and 63.6% in the highest, against 82.4% in the middle.
And a study of 313 middle-aged men found circulating estradiol independently predicted three-year progression of carotid intima-media thickness.
Now look at the third one again. The most cited demonstration that men have a U-shaped estradiol risk curve measured estradiol by immunoassay. The low arm of that curve sits exactly where the immunoassay has 13.3% sensitivity, and the cohort was a heart failure population, meaning high inflammation, which is the condition under which immunoassay estradiol has been shown to drift.
That does not make the finding wrong. The mass spectrometry cohort found a low-end mortality signal too, independently, so the shape is probably real. But it does mean that the exact position of the bottom of that curve, the number a man would actually want to steer by, has never been established using a method capable of reading that range.
The optimal estradiol target for men is being debated to the decimal point on the back of measurements that cannot resolve it.
Liquid chromatography tandem mass spectrometry separates molecules physically by chromatography and then identifies them by mass to charge ratio. A compound that merely resembles estradiol does not get counted as estradiol. That is the entire difference.
Published routine LC-MS/MS methods reach limits of quantitation around 1 to 1.3 pg/mL. A man's estradiol sits roughly ten to twenty times above that floor, which is the margin you want between the value and the noise. The immunoassay has no such margin.
An Endocrine Society position statement identified the need for a routinely applicable assay capable of measuring low estradiol in adult men, and clinical chemistry method papers have been citing that gap ever since. One such method, validated against certified reference material, reported a correlation with direct immunoassay of only r squared = 0.64 for estradiol.
The technology to do this correctly has existed for close to twenty years. It is simply not what shows up by default on a hormone panel.
Ask which method was used. If a panel reports estradiol for a man without naming the method, it is almost certainly immunoassay. The labels worth looking for are "sensitive estradiol," "ultrasensitive estradiol," or "estradiol by LC-MS/MS."
Do not trend across methods. An immunoassay estradiol and a mass spectrometry estradiol are different measurements with different biases. A change between two draws run on different methods is not evidence of a change in you.
Read the two directions differently. A single low immunoassay estradiol in a man carries very little information, because that assay was never able to see the low range. A high one is worth a second look on a better method, because high is the one direction the assay handles.
This series keeps arriving at reference ranges built on the wrong population. This one is a different failure and a worse one. The range is not the problem here. The measurement underneath the range is the problem.
A bad reference range at least tells you what it assumes, and you can argue with the assumption. An assay operating below its useful range tells you nothing about its own uncertainty. It prints a value to one decimal place, and that value looks exactly like a good one.
Educational content only. Not medical advice. Nothing here is a recommendation to start, stop, or change any medication, hormone protocol, or supplement. Assay selection and interpretation of hormone results belong with a licensed clinician who knows your history.
Studies referenced here were retrieved from PubMed.
Educational content — not medical advice. Effects described are drawn from cited research in study subjects.